Biocon receives UK insulin approval and MarketsMOJO downgrades Biocon stock

Published on 10/02/2026 at 14:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Axis Direct set a INR 424 target for Biocon stock on September 21, 2026. Q1 FY27 revenue rose 10.00 percent to INR 43.36 billion.

Biocon, INE376G01013, Illustration mit AI erstellt.

Biocon Limited (INE376G01013) received UK approval for its Malaysia insulin fill-finish unit on September 28, 2026, while MarketsMOJO reported a Hold-to-Sell downgrade dated September 30, 2026. The regulatory approval supports additional insulin manufacturing capacity, but the rating change highlights the pressure on profitability and leverage.

Insulin capacity expands in Malaysia

Machine Maker reported on September 28, 2026, that the UK Medicines and Healthcare products Regulatory Agency approved Biocon's new drug product fill-finish line for Semglee at the Malaysian insulin facility. The approval follows an earlier European clearance and adds to Biocon's international manufacturing network.

The unit covers insulin glargine production for international markets. For Biocon, the development is operationally relevant because the company is expanding capacity while its biosimilars business supplies the strongest growth contribution in the latest reported quarter.

Q1 revenue rises as services contract

In Q1 FY27, ended June 30, 2026, consolidated revenue rose 10.00 percent year over year to INR 43.36 billion from INR 39.42 billion, according to Alpha Inflection. Consolidated net profit reached INR 1.41 billion, while biosimilars revenue increased 16.00 percent year over year to INR 28.55 billion.

The mix remains uneven. The same Q1 FY27 filing summary showed the services segment contracting 16.00 percent year over year, even as biopharma revenue grew 17.00 percent. That contrast gives the Malaysia approval greater strategic weight because future capacity gains need to offset weakness in services and sustain the higher-growth biopharma businesses.

Ratings split over profitability

Trendlyne reported on September 21, 2026, that Axis Direct named Biocon its Pick of the Week and set a INR 424 target. The recommendation contrasts with the later Sell downgrade, leaving capacity expansion and earnings quality as the key competing interpretations of the stock.

MarketsMOJO cited a 3.72 percent return on capital employed for the half-year period and a 4.47 times debt-to-EBITDA ratio in its September 30 assessment. Those figures explain why the growth story has not translated into a uniformly positive rating view.

Market value stays below yearly high

Biocon was last quoted at INR 370.90 on the BSE on October 1, 2026 at 3:28 p.m. IST. The quote stood 17.02 percent below the 52-week high of INR 447.00 and 9.75 percent above the 52-week low of INR 337.95, while market capitalization was INR 505.7 billion.